DC-CIK治疗血液系统肿瘤的研究进展  

The research progress of DC-CIK treatment of blood system tumor

作　　者：刘德[1] 王一[2] 

机构地区：[1]延安大学医学院,陕西延安716000 [2]陕西省人民医院,陕西西安710068

出　　处：《医药前沿》2016年第12期6-8,共3页Journal of Frontiers of Medicine

摘　　要：树突状细胞（DC）是目前已知功能最强的专职抗原呈递细胞，而细胞因子诱导的杀伤细胞（CIK）具有非主要组织相容性复合体限制性，是一种广谱抗瘤免疫活性细胞，近年来大量体内外研究表明，DC—CIK生物免疫治疗不仅能改善血液肿瘤患者预后，提高放化疗耐受性，延长缓解期，清除微小残留病灶，而且能一定程度上逆转耐药，因此成为肿瘤生物免疫疗法中的研究热点。现就DC和CIK的生物学特性、抗肿瘤机制、DC-CIK细胞治疗恶性血液病的基础及临床研究予以综述。Dendritic cells CDC） is the most powerful professional antigen-presenting cells are now known to function, and cytokine induced killer cells CCIK）, with the major histocompatibility complex restrictive, is a kind of broad-spectrum antineoplastic immune active cells. In recent years a large number of studies have shown that DC - CIK biological immune therapy, not only can improve the prognosis of patients with tumor blood, remove tiny residual lesions, but also to a certain extent, to reverse drug resistance. This paper reviews the biological characteristics of DC and CIK, antitumor mechanism, DC - the basis of CIK cells to treat malignancies, and clinical research.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 血液肿瘤 生物免疫疗法 

分 类 号：R730.5[医药卫生—肿瘤]